|Last Price||Today's Change||52-Week Range||Trading Volume|
|5.68||-0.22 (-3.73%)||1.26 - 6.81||4.8 million (Above Avg)|
Market data as of 12:47PM 10/06/15. Quotes are delayed by at least 15 min.
Exelixis Announces Positive Overall Survival Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma
10/06/2015 1:00 AM ET